Impact of Treating Insomnia Symptoms on Abstinence from Smoking



Vijay Nitturi¹, George Kypriotakis, PhD², Maher Karam-Hage, MD²

Department of Behavioral Science, The University of Texas MD Anderson Cancer Center², Houston, TX

Background

- Quitting smoking prevents cancer in healthy people.¹
- Quitting smoking at the time of a cancer diagnosis can increase survivorship in cancer patients by 30-40%.¹
- Insomnia, a disorder in which patients have trouble falling/staying asleep, can make it harder to quit smoking.²
- We set out to see if treating insomnia symptoms would help patients at MD Anderson's Tobacco Treatment Program quit smoking.

Methods

- Data was extracted from our psychiatry database and the electronic health records (EHR) of patients who participated in MD Anderson's (MDA) Tobacco Treatment Program.
- Initial, middle, and late insomnia were assessed with the brief 4question Jenkins sleep questionnaire, abstinence was based on subject report, severity of nicotine dependence was based on the Fagerström test at baseline, and medications prescribed for insomnia were collected from the EHR.
- We report abstinence by 7-day point prevalence, as a measure of 7 continuous days in the prior week in which cigarettes were not smoked at 3, 6, and 9 months after starting tobacco cessation treatment.
- The relationship between insomnia score and abstinence was evaluated after controlling for several possible confounders e.g. severity of nicotine dependence, anxiety, depression, and the severity of measured insomnia symptoms.
- Analyses were conducted after propensity score matching was used to match participants according to each of the characteristics in Table 1.





Table 1. Participant Ch
Male
White
Anxiety
Panic
Alcohol
Major Depression
Depression
Age
Center for Epidemiolog
Studies Depression Scal
Fagerström Test for Nic
Dependence





score at initial psychiatric evaluation.

University of Houston¹, Houston, TX

aracteristics	Not Treated for Insomnia	Treated for Insomnia
	% (N)	% (N)
	58.41 (1382)	74.10 (123)
	79.67 (1885)	79.52 (132)
	29.90 (690)	42.33 (69)
	13.60 (314)	29.45 (48)
	11.35 (262)	8.59 (14)
	25.65 (592)	41.10 (67)
	40.60 (937)	57.06 (93)
	Mean (SD)	Mean (SD)
	53.81 (10.92)	53.01 (11.77)
c e-Total	18.88 (11.99)	24.62 (12.44)
otine	4.75 (2.27)	4.74 (2.31)



Results

- In propensity score matched analyses, patients treated for insomnia were more likely to abstain from smoking than patients not treated for insomnia 9 months after the start of tobacco cessation treatment. (p = 0.013)
- However, at the 9-month abstinence point, patients treated for insomnia with sleep scores greater than 14 had lower abstinence rates than patients not treated for insomnia (Figure 2).
- At 3- and 6-month abstinence points, treatment for insomnia did not significantly improve abstinence rates compared with the nontreatment group.

Discussion/Conclusions

- The differential impact of treating insomnia is likely to be due to severe insomnia being a marker of other psychiatric disorders; therefore, treating it might not translate to improved ability to quit among those patients.
- · However, treating individuals with milder or moderate levels of insomnia may have a positive benefit on their tobacco abstinence outcomes.
- Therefore, treating insomnia symptoms among cancer survivors and patients trying to quit smoking can be beneficial in preventing recurrence of cancer or development of a second primary cancer.
- Future analyses will aim to control for the co-occurrence of other psychiatric disorders and their impact on the ability to quit smoking.

References

- 1. National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. The Health Consequences of Smoking: 50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention: 2014.
- 2. Pasman JA, Smit DJA, Kingma L, Vink JM, Treur JL, Verweij KJH. Causal relationships between substance use and insomnia [published correction appears in Drug Alcohol Depend. 2020 Nov 1;216:108313]. Drug Alcohol Depend. 2020;214:108151. doi:10.1016/j.drugalcdep.2020.108151

Acknowledgements: This presentation was supported by a training grant from the National Cancer Institute (R25CA056452, Dr. Shine Chang, Principal Investigator). The project was also approved by MD Anderson's Institutional Review Board. For further information, please contact Vijay Nitturi at vnitturi@MDAnderson.org.

THE UNIVERSITY OF TEXAS MDAnderson **Cancer** Center